Literature DB >> 8259811

Neonatal tetanus in Peru: risk assessment with modified enzyme-linked immunosorbent assay and toxoid skin test.

L Vernacchio1, G Madico, M Verastegui, F Diaz, T S Collins, R H Gilman.   

Abstract

We used a modified enzyme-linked immunosorbent assay (ELISA) to investigate tetanus immunity in 232 pregnant Peruvian women. One hundred forty-two (61.2%) had protective antitoxin titers (> or = 0.01 IU/mL). Protective titers correlated positively with the number of toxoid doses reported during the current pregnancy. A majority of women reporting no toxoid doses during the current pregnancy had at least one prenatal health care visit. We evaluated a toxoid skin test in 44 of the subjects, but it correlated poorly with the ELISA. The modified ELISA is a useful in vitro method for studying tetanus immunity in the developing world.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8259811      PMCID: PMC1694911          DOI: 10.2105/ajph.83.12.1754

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  15 in total

1.  ELISA for the routine determination of antitoxic immunity to tetanus.

Authors:  O Simonsen; M W Bentzon; I Heron
Journal:  J Biol Stand       Date:  1986-07

2.  Hypersensitivity to tetanus toxoid.

Authors:  M A Facktor; R A Bernstein; P Fireman
Journal:  J Allergy Clin Immunol       Date:  1973-07       Impact factor: 10.793

3.  Impaired in vitro cell-mediated immunity to rubella virus during pregnancy.

Authors:  Y H Thong; R W Steele; M M Vincent; S A Hensen; J A Bellanti
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

4.  The use of toxoid for the prevention of tetanus neonatorum. Final report of a double-blind controlled field trial.

Authors:  K W Newell; A Dueñas Lehmann; D R LeBlanc; N Garces Osorio
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

5.  New concepts on tetanus immunization: naturally acquired immunity.

Authors:  R Veronesi; H Cecin; A Corrêa; J Tavares; C Moraes; O J Bertoldo
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1975

6.  Sero-survey of diphtheria and tetanus antitoxin.

Authors:  S N Ray; K Ray; S S Grover; R S Sharma; S P Sharma
Journal:  Indian J Med Res       Date:  1978-12       Impact factor: 2.375

7.  Evaluation of cutaneous response to tetanus antigen to document immunization: preliminary observations.

Authors:  S Bhatia; K Ray; R Mathur; T P Yadav; A N Rai Chowdhary; S S Grover; I Narayanan
Journal:  Indian Pediatr       Date:  1985-04       Impact factor: 1.411

8.  Response to single dose of tetanus vaccine in subjects with naturally acquired tetanus antitoxin.

Authors:  F D Dastur; V P Awatramani; S K Dixit; J A D'Sa; N D Cooverji; M P Anand
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

9.  Reduction of neonatal tetanus by mass immunization of non-pregnant women: duration of protection provided by one or two doses of aluminium-adsorbed tetanus toxoid.

Authors:  R E Black; D H Huber; G T Curlin
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

10.  Neonatal tetanus: countdown to 1995.

Authors:  C M da Silveira; C A de Quadros
Journal:  World Health Forum       Date:  1991
View more
  3 in total

Review 1.  Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus.

Authors:  V Dietz; J B Milstien; F van Loon; S Cochi; J Bennett
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

2.  Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru.

Authors:  G Madico; G Salazar; J McDonald; W Checkley; M Calderón; M Verastegui; R H Gilman
Journal:  Clin Diagn Lab Immunol       Date:  1996-11

3.  Tetanus immunization in pregnant women. Serum levels of antitetanus antibodies at time of delivery.

Authors:  I Maral; M Cirak; F N Aksakal; Z Baykan; F Kayikcioglu; M A Bumin
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.